Dr. Ars India Labs Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.40 M
as on 17-11-2024
- Satisfied Charges ₹ 3.60 M
as on 17-11-2024
- Revenue -14.76%
(FY 2023)
- Profit -39.31%
(FY 2023)
- Ebitda 0.16%
(FY 2023)
- Net Worth 11.65%
(FY 2023)
- Total Assets -10.77%
(FY 2023)
About Dr. Ars India Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.40 M. The company has closed loans amounting to ₹3.60 M, as per Ministry of Corporate Affairs (MCA) records.
Ajmeerkhan Mohamed and Kalanjiyam Hakkim serve as directors at the Company.
- CIN/LLPIN
U24239TN2003PTC050810
- Company No.
050810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Madurai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dr. Ars India Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajmeerkhan Mohamed  | Director | 24-Jul-2015 | Current |
| Kalanjiyam Hakkim | Director | 24-Jul-2015 | Current |
Financial Performance of Dr. Ars India Labs.
Dr. Ars India Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.76% decrease. The company also saw a substantial fall in profitability, with a 39.31% decrease in profit. The company's net worth Soared by an impressive increase of 11.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Ars India Labs?
In 2023, Dr. Ars India Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 27 Dec 2021 | ₹4.50 M | Open |
Canara Bank Creation Date: 23 Aug 2021 | ₹0.40 M | Open |
Canara Bank Creation Date: 19 May 2016 | ₹2.00 M | Open |
How Many Employees Work at Dr. Ars India Labs?
Unlock and access historical data on people associated with Dr. Ars India Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Ars India Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Ars India Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
